Blog - QualityStocks

MondayDec 01, 2025 2:00 pm

SPARC AI Inc. (OTCQB: SPAIF) (CSE: SPAI) Differentiates from Drone Surveillance Competitors with GPS-Free, Software-First, and Continuous Intelligence

Disseminated on behalf of  SPARC AI Inc. (OTCQB: SPAIF) (CSE: SPAI) and may include paid advertising. SPARC AI Inc. offers autonomous navigation and target acquisition software for drones and other robotic systems The company’s technology differentiates from competitors by not relying on sensors, but having a software-first model, and offering continuous geospatial and behavioral intelligence At the heart of the company’s technology is Overwatch, an intelligence interface that combines targeting and navigation into a single capability SPARC AI (OTCQB: SPAIF) (CSE: SPAI), a drone technology and software developer, has created a target acquisition system and autonomous navigation software for drones…

MondayDec 01, 2025 1:53 pm

QualityStocksNewsBreaks – Strawberry Fields REIT, Inc. (NYSE AMERICAN: STRW) CEO to Present at NobleCon21

Strawberry Fields REIT (NYSE AMERICAN: STRW) a self-administered REIT focused on healthcare-related properties, said Chairman and CEO Moishe Gubin will present at NobleCon21 on Dec. 3 at 4:30 p.m. Eastern at Florida Atlantic University’s Executive Education Complex. A high-definition webcast will be available on the NobleCon and Channelchek websites and will remain archived for 90 days. To view the full press release, visit https://ibn.fm/wOMyT About Strawberry Fields REIT Strawberry Fields REIT, Inc., is a self-administered real estate investment trust engaged in the ownership, acquisition, development and leasing of skilled nursing and certain other healthcare-related properties. The Company’s portfolio includes 142…

MondayDec 01, 2025 1:15 pm

Soligenix Inc. (NASDAQ: SNGX) Reaches Key Enrollment Milestone in Phase 3 Trial with Encouraging Blinded Response Rate

The enrollment milestone represents a crucial step forward for the FLASH2 study, which builds upon the previous statistically significant Phase 3 FLASH study. The promising early results are further corroborated by an ongoing investigator-initiated study being conducted at the University of Pennsylvania. Soligenix is positioning itself to potentially deliver the first FDA-approved photodynamic therapy specifically indicated for CTCL. In a pivotal advancement for patients suffering from a rare form of skin cancer, Soligenix (NASDAQ: SNGX) has achieved a critical clinical trial milestone that brings its investigational treatment significantly closer to potential FDA approval. The company announced that is has completed…

MondayDec 01, 2025 12:25 pm

QualityStocksNewsBreaks – Nevada Organic Phosphate Inc. (CSE: NOP) Releases Updated Murdock Mountain Project Factsheet

This article has been disseminated on behalf of Nevada Organic Phosphate Inc. and may include paid advertising. Nevada Organic Phosphate (CSE: NOP) published an updated Project Factsheet featuring new graphics that highlight the scale and consistency of the Murdock Mountain Upper Phosphatic Zone, with drilling intersecting the Meade Peak stratigraphy as predicted by the company’s geological model. Leadership said the refreshed visuals strengthen confidence in the project’s potential viability, and laboratory assay results will be released once received and validated. To view the full press release, visit https://ibn.fm/5PHTb About Nevada Organic Phosphate Inc. NOP is a junior exploration company with…

MondayDec 01, 2025 12:02 pm

QualityStocksNewsBreaks – MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) Accelerates CEO Start Amid Natural Hydrogen Milestones

This article has been disseminated on behalf of MAX Power Mining and may include paid advertising. MAX Power Mining (CSE: MAXX) (OTC: MAXXF) (FRANKFURT: 89N) advanced the start date of incoming CEO and Director Ranjith Narayanasamy to Dec. 1, 2025, one week earlier than previously announced, as the company begins targeted zone testing at Lawson, Canada’s first deep well drilled specifically for Natural Hydrogen. MAX Power is also progressing a fully funded second well at Bracken within its 1.3-million-acre Natural Hydrogen land package, while outgoing CEO Mansoor Jan moves to lead the company’s U.S. subsidiary, Homeland Critical Minerals. To view…

MondayDec 01, 2025 11:27 am

QualityStocksNewsBreaks – New Pacific Metals Corp. (TSX: NUAG) (NYSE American: NEWP) Reports Voting Results from Annual Meeting

This article has been disseminated on behalf of New Pacific Metals Corp. and may include paid advertising. New Pacific Metals (TSX: NUAG) (NYSE American: NEWP) said all matters presented at its Oct. 24, 2025 annual meeting were approved by shareholders, with 144,270,137 common shares represented, or 78.53 percent of eligible votes. Director nominees Dickson Hall, Martin Wafforn, Maria Tang, Jalen Yuan, Paul Simpson, and Myles Gao were each elected with approval levels ranging from 96.52 percent to 99.90 percent. To view the full press release, visit https://ibn.fm/3u3Ae About New Pacific  New Pacific is a Canadian exploration and development company with…

MondayDec 01, 2025 11:10 am

QualityStocksNewsBreaks – SEGG Media Corporation (NASDAQ: SEGG, LTRYW) Announces Leadership Changes as Board Appoints Robert Stubblefield Interim CEO

SEGG Media (NASDAQ: SEGG, LTRYW) said its Board terminated CEO, Secretary and President Matthew McGahan and removed him as Chairman, appointing CFO Robert Stubblefield as Interim CEO, Secretary and President and naming Marc Bircham Chairman. McGahan will remain a Director until his term expires at the upcoming annual meeting. The Company said the leadership transition supports its next phase of growth as it scales Sports.com, Concerts.com and Lottery.com, with more than 102 million views across platforms in 2025, and prepares for planned acquisitions. Stubblefield said the focus is on financial stability, disciplined execution and rebuilding shareholder value, while guiding expansion…

MondayDec 01, 2025 9:50 am

QualityStocksNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at NobleCon21

NRx Pharmaceuticals (NASDAQ: NRXP) said Founder, Chairman and CEO Jonathan Javitt, M.D., M.P.H., will present at NobleCon21 on Dec. 3 at 4:30 p.m. EST, offering an update on the company’s expanded focus in investigational drugs, medical devices, and interventional psychiatric therapies for suicidal depression, PTSD, and related conditions, as well as progress in generating clinical revenue since NobleCon 2024. To view the full press release, visit https://ibn.fm/NNleU About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals, Inc. (www.nrxpharma.com), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain,…

MondayDec 01, 2025 9:25 am

QualityStocksNewsBreaks – ESGold Corp. (CSE: ESAU) (OTCQB: ESAUF) Raises Private-Placement Maximum to $4.5 Million on Strong Demand

This article has been disseminated on behalf of ESGold Corp. and may include paid advertising. ESGold (CSE: ESAU) (OTCQB: ESAUF) increased the maximum gross proceeds of its planned non-brokered private placement to $4,505,000 after strong investor interest, now offering up to 5.3 million flow-through shares at $0.85 each with Red Cloud Securities as exclusive finder. Proceeds will fund exploration at the Montauban Property in Quebec and will be allocated to Qualifying Expenditures under federal and provincial tax rules. Closing is expected on or about Dec. 8, 2025, subject to regulatory approvals, with all securities carrying a four-month-plus-one-day hold period. To…

MondayDec 01, 2025 9:15 am

QualityStocksNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Outlines Regulatory Strategy After NSE Decision on ECG Synthesis Software

HeartBeam (NASDAQ: BEAT), a medical technology company developing personalized cardiac-care insights, detailed its strategy following receipt of a Not Substantially Equivalent decision for its 510(k) submission covering its 12-lead ECG Synthesis Software. The Company has been in active discussions with FDA review staff, which have signaled willingness to work toward a constructive resolution. HeartBeam said its VALID-ECG clinical study met endpoints and that remaining FDA concerns may be resolved through revised labeling. To advance the process, the Company plans to pursue multiple parallel paths—including a formal appeal or a 510(k) resubmission—and believes recent interactions indicate a viable path forward under…

Site Search

Company Search